Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

158 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study.
Roila F, Ruggeri B, Ballatori E, Fatigoni S, Caserta C, Licitra L, Mirabile A, Ionta MT, Massidda B, Cavanna L, Palladino MA, Tocci A, Fava S, Colantonio I, Angelelli L, Ciuffreda L, Fasola G, Zerilli F. Roila F, et al. Among authors: fasola g. Ann Oncol. 2015 Jun;26(6):1248-1253. doi: 10.1093/annonc/mdv132. Epub 2015 Mar 5. Ann Oncol. 2015. PMID: 25743855 Free article. Clinical Trial.
Preoperative treatments in borderline resectable and locally advanced pancreatic cancer: Current evidence and new perspectives.
de Scordilli M, Michelotti A, Zara D, Palmero L, Alberti M, Noto C, Totaro F, Foltran L, Guardascione M, Iacono D, Ongaro E, Fasola G, Puglisi F. de Scordilli M, et al. Among authors: fasola g. Crit Rev Oncol Hematol. 2023 Jun;186:104013. doi: 10.1016/j.critrevonc.2023.104013. Epub 2023 Apr 26. Crit Rev Oncol Hematol. 2023. PMID: 37116817 Review.
A randomised phase II study of docetaxel/oxaliplatin and docetaxel in patients with previously treated non-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group trial (ATOM 019).
Belvedere O, Follador A, Rossetto C, Merlo V, Defferrari C, Sibau AM, Aita M, Dal Bello MG, Meduri S, Gaiardo M, Fasola G, Grossi F. Belvedere O, et al. Among authors: fasola g. Eur J Cancer. 2011 Jul;47(11):1653-9. doi: 10.1016/j.ejca.2011.03.020. Epub 2011 Apr 20. Eur J Cancer. 2011. PMID: 21514147 Clinical Trial.
Unplanned presentations of cancer outpatients: a retrospective cohort study.
Aprile G, Pisa FE, Follador A, Foltran L, De Pauli F, Mazzer M, Lutrino S, Sacco CS, Mansutti M, Fasola G. Aprile G, et al. Among authors: fasola g. Support Care Cancer. 2013 Feb;21(2):397-404. doi: 10.1007/s00520-012-1524-6. Epub 2012 Jun 22. Support Care Cancer. 2013. PMID: 22722887
Medical oncology: in search of a definition.
Numico G, Fasola G. Numico G, et al. Among authors: fasola g. Ann Oncol. 2014 May;25(5):1075-6. doi: 10.1093/annonc/mdu059. Epub 2014 Feb 20. Ann Oncol. 2014. PMID: 24558026 Free article. No abstract available.
PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.
Schwartzberg LS, Rivera F, Karthaus M, Fasola G, Canon JL, Hecht JR, Yu H, Oliner KS, Go WY. Schwartzberg LS, et al. Among authors: fasola g. J Clin Oncol. 2014 Jul 20;32(21):2240-7. doi: 10.1200/JCO.2013.53.2473. Epub 2014 Mar 31. J Clin Oncol. 2014. PMID: 24687833 Clinical Trial.
Phase II randomized study of vandetanib plus gemcitabine or gemcitabine plus placebo as first-line treatment of advanced non-small-cell lung cancer in elderly patients.
Gridelli C, Novello S, Zilembo N, Luciani A, Favaretto AG, De Marinis F, Genestreti G, Crinò L, Grossi F, Caffo O, Ferraù F, Cruciani G, Brandes AA, Galetta D, Barni S, Fasola G, Cerea G, Ferrari S, Iannacone C, Ciardiello F. Gridelli C, et al. Among authors: fasola g. J Thorac Oncol. 2014 May;9(5):733-7. doi: 10.1097/JTO.0000000000000120. J Thorac Oncol. 2014. PMID: 24722160 Free article. Clinical Trial.
Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study).
Leone F, Marino D, Cereda S, Filippi R, Belli C, Spadi R, Nasti G, Montano M, Amatu A, Aprile G, Cagnazzo C, Fasola G, Siena S, Ciuffreda L, Reni M, Aglietta M. Leone F, et al. Among authors: fasola g. Cancer. 2016 Feb 15;122(4):574-81. doi: 10.1002/cncr.29778. Epub 2015 Nov 5. Cancer. 2016. PMID: 26540314 Free article. Clinical Trial.
158 results